Marshall Wace
RPTP

Marshall Wace’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Marshall Wace’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-386,825
Closed -$1.78M – 1330
2016
Q1 		$1.78M Buy
+386,825
New +$1.55M 0.02% 584
2015
Q3 		– Sell
-381,765
Closed -$6.03M – 1242
2015
Q2 		$6.03M Buy
+381,765
New +$4.64M 0.08% 270

Other funds holding RPTP

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's RPTP Position: Q2 2016 in Review

Marshall Wace sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q2 2016, closing a stake of 386,825 shares — an estimated $1.78M sold.

Marshall Wace first reported a position in RPTP in Q2 2015 and held it in 2 quarters. The position peaked at $6.03M in Q2 2015. 93 funds tracked by Wall St. Rank hold RPTP as of Q2 2016.

  • Marshall Wace reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Marshall Wace sold 386,825 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q2 2016, an estimated $1.78M.
  • Marshall Wace first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2015 and held it in 2 quarters.
  • Marshall Wace's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $6.03M in Q2 2015.
  • 93 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q2 2016.

Based on Marshall Wace's 13F filing for Q2 2016, filed 12 Aug 2016.